From June 16-18, at Shanghai New International Expo Center, CPHI China 2026 – the Biotechnology Exhibition Area will focus on the core theme of “Independent Innovation + Overseas Markets”, creating a high-level platform for cutting-edge technologies and innovative achievements during the conference. Specifically, Hall W9 will feature a “Cutting-Edge Technologies and Innovation Zone” covering popular areas such as cell/genetic drugs, nucleic acid drugs, antibody drugs, and peptides. It connects pre-clinical research and clinical translation needs, providing a platform for showcasing and exchanging new technologies and new modalities. As a key academic segment of this exhibition, the Drug Development and Technological Innovation Exchange Conference will be held June 16, at the Convention Center – Hall W9 . The exchange conference will include two parallel forums— " "in-vivo CAR-T" "R&D and Delivery Breakthrough Forum" and "mRNA Delivery Optimization and Innovation Frontier Forum" co-hosted by China Pharmaceutical and Health Products Import and Export Chamber of Commerce, Shanghai Bohua International Exhibition Co., Ltd., and TanSi Biotech . Both forums focus on "mRNA delivery systems" "breakthroughs in bottlenecks and next-generation technology routes, as well as the latest explorations and clinical translation challenges of in-vivo CAR-T" to bring together top-level expertise from industry, academia, and healthcare. The goal is to connect the critical link from basic research to industrial implementation, injecting original innovation into the internationalization of biomedicine. Tickets are selling out quickly; we invite industry professionals to join this year’s collaborative innovation and global-connected event! Details of the special meeting Meeting name: "Two Parallel Special Forums: in-vivo CAR-T R&D and Delivery Breakthrough & mRNA Delivery Optimization and Innovation Frontier" Hosts: China Pharmaceutical and Health Products Import and Export Chamber of Commerce, Shanghai Bohua International Exhibition Co., Ltd., and TanSi Biotech Date: June 16, 2026 (all-day meeting) Location: Shanghai New International Expo Center (Hall W9) Attendance: 200+ Scan the code to register "in-vivo CAR-T R&D and Delivery Breakthrough Forum" "Free participation, first come, first served" "Limited seats available; scan the code now to secure your spot" "mRNA Delivery Optimization and Innovation Frontier Forum" "Free participation, first come, first served" "Limited seats available; scan the code now to secure your spot" ① Scan the QR code above to fill in registration information and save the success screenshot (industry chain upstream and downstream groups) ② Final interpretation rights belong to the organizers Agenda Morning "[in-vivo CAR-T R&D and Delivery Breakthrough] Special Session" 10:00-10:30 "Specific delivery of tLNP to T/NK cells" "Advantages of tLNP specific delivery" "Optimization of delivery efficiency for T/NK cells" Dr. Wang Liqun, Chairman, Xingyiong Biotech 10:30-11:00 "Breakthroughs in LNP carrier technology" "and progress in in-vivo CAR-T applications" "Rational design of ionizable lipids and RNA drug delivery" "Development directions of in-vivo therapies" Mr. Zhu Yuchao, General Manager, HanXin Biotech 11:00-11:30 "In Vivo CAR-Tumor" "The next breakthrough in immunotherapy:" "Disrupting immune cell therapy" "Sharing progress in in-vivo CAR-T research using lentiviral carriers" "Current challenges and future prospects of in-vivo CAR-T" Dr. Zhou Guoqing, CEO, Rongrui Medicine 11:30-12:00 "Technology driving new developments in cell therapy with in-vivo CAR-T" "Discussion of advantages and disadvantages of different carriers for in-vivo CAR-T" "Pipeline progress of in-vivo CAR-T" Dr. Chen Limo, Chairman, Queenboat Pharmaceuticals 12:00-12:30 "Analysis of the current state of the in-vivo CAR-T industry" "Current industry situation of in-vivo CAR-T" "Prospects analysis of the in-vivo CAR-T industry" Ms. Li Qian, Executive Director, Frost & Sullivan Afternoon "[mRNA Delivery Optimization and Innovation Frontier] Special Session" 14:00-14:30 "RNA genome modified sequence drugs" "Value of RNA AI large models in drug development" "Coordination between modified sequences and AI models" "Accelerating drug development and optimization" Professor Yang Haitao, Founder, RemiOna 14:30-15:00 "R&D and clinical progress of mRNA immunotherapy drugs" "Regarding HPV-related precancerous lesions" "RG002 delivery system and clinical data" Dr. Zhang Weiguo, R&D VP, Renjing Biotech 15:00-15:30 "AI-driven personalized precision treatment for tumors" "AI enabling personalized diagnosis and treatment decisions" "Precision targeting of tumor neoantigens" Dr. Mo Fan, Co-founder & CEO, Niu'anjin Biotech 15:30-16:00 "AI-driven superbug mRNA vaccine development" "AI screening of conserved antigens to overcome genetic constraints" "Integrating AI and mRNA to enable rapid vaccine iteration" Dr. Fei Caiyi, Co-founder & Vice President, Chengshi Biotech Guest introductions Dr. Wang Liqun has extensive professional skills and research management experience in pharmaceutical and biotech fields in the US and China. He has worked in important management positions at Procter & Gamble, Bristol Myers Squibb, AstraZeneca, andGSK China R&D Centers for nearly 30 years, participating in and leading the research and translation of multiple new drugs. Later, he served as Chief Operating Officer and General Manager of Stem Cell Division at SybiMann Biotech, responsible for the production, pharmacology, and clinical research of cell therapy products. In 2017, Dr. Wang became the founding president of Fosun Kite, leading his team to implement the technology of Yikida, produce and register it for clinical use within three years, making it the first CAR-T product approved by the Chinese FDA. In 2021, he founded Xingyiong Biotech, developing iPSC-derived general-purpose, mass-produced, tumor- and autoimmune disease-treating dual-platform CAR-iNK/CAR-iT cell therapy products, with early products already in clinical validation stage. Dr. Wang has published dozens of scientific papers and monographs throughout his career and obtained multiple national invention patent authorizations. He also holds social positions such as Vice President of the Cell Therapy Research and Application Society of the Chinese Society of Cell Biology and Deputy Chairperson of the CGT Committee of the Shanghai Biomedical Association. He has received honors such as Pudong Pearl Plan Entrepreneurship Leadership Talent and Shanghai White Orchid Memorial Award. Dr. Zhu Yuchao, Co-founder & General Manager of HanXin Biotech, is a Suzhou Gusu Leading Talent and Park Leading Talent. He has authorized or accepted more than ten patents. In 2024, he was named a Young Influencer in the China Biopharmaceutical Industry Innovation List U45, Vice Chairperson of the CBIITA Consortium Cell Therapy Committee, and planner and host of the SAPA China 2025 Cell Therapy Forum. With over 10 years of biopharmaceutical industrialization experience, he helped establish and transfer technology for the first sterile formulation factory in China at Eli Lilly. He also contributed to the launch of China’s first CAR-T cell therapy product and the successful launch of China’s first overseas PD-1 drug. Dr. Zhou Guoqing obtained his Ph.D. in molecular biology from Sweden and has worked as a research scientist in Canada and the US, accumulating solid academic and research foundations. He has over 20 years of experience in new drug research and focuses on the transformation and industrialization of innovative therapies. Dr. Zhou is a serial entrepreneur who founded and sold two biotech companies. He has held key leadership positions such as CEO, Chief Science Officer, and Chairman in enterprises, possessing rich strategic and operational management experience. He also served as Chief Operating Officer of SiBiono GeneTech, participating in the development of the world’s first viral gene therapy drug "Gendicine" based on adenovirus vectors expressing p53 gene, which is milestone in gene therapy. With a deep background across academia and industry, Dr. Zhou invented the new treatment method of in-vivo CAR-Tumor with engineered in-vivo cancer cells and is committed to promoting biological technology innovation and clinical translation, facilitating the application of cutting-edge research results in real medical practice. Dr. Chen Limo studied and worked at Harvard University and Anderson Cancer Center from 2005 to 2021, receiving 16 important awards. Based on his discovery of new CD38 functions, global pharmaceutical companies have developed several new drugs. In 2024, he founded Queenboat Pharmaceuticals, whose development was reported by CCTV. He was invited to the Xinhua News Agency studio to provide insights for the series report "Confidence of the Chinese Economy" from a pharmaceutical industry perspective, with key parts published on Xinhua Net. He is a Top 10 Innovator of the New Era in 2024, Responsible Business Leader of 2024, Shaping the Future Person of the CCTV Era in 2025, and a think tank expert of the China Future Research Association. His company was awarded the "National Brand. Shining World" Key Promotion Brand and Excellent Case of Private Enterprise Technology Innovation. Ms. Li Qian is the Executive Director of Frost & Sullivan China’s medical team, specializing in cell immunotherapy industry. She has extensive knowledge and experience in IPO industry consulting, new product market access, and pricing. She actively participates in corporate investment and financing plans, achieving corporate growth through industry chain resource integration, park implementation, and external promotion, accumulating rich industry experience. Mr. Yang Haitao is a Ph.D. in Medical Genetics from Uppsala University in Sweden, a postdoctoral fellow in Tumor Genetics and Neurogenetics at University of California, San Francisco/Los Angeles, and a researcher in Rheumatology at the School of Medicine, University of California, San Diego. After returning to China, he became a Qianjiang Scholar Distinguished Professor and a researcher at Sun Yat-sen University Shenzhen Research Institute. Currently, he is an industry professor at Southern University of Science and Technology’s Cell and Gene Therapy Research Center. He is the founder of RemiOna (Guangzhou) Biopharmaceutical Technology Co., Ltd., having long been involved in tumor genomics, tumor mRNA vaccines, and RNA large model research. Dr. Zhang Weiguo is the R&D VP at Renjing Biotech, leading the establishment of mRNA purification and multiple analysis methods, responsible for the company’s mRNA technology platform, pipeline expansion, and early research. He is a "Mass Innovation" talent in Jiangsu Province, PI of the "Unveiled Challenge and Leadership" project of the National Innovation Center for Cell Therapy and a key technical project PI in Suzhou. Previously, he was an assistant professor at Lawrence Berkeley National Laboratory and a postdoctoral fellow at University of California, Berkeley, and a Ph.D. in genetics from Iowa State University. Dr. Mo Fan is: "Senior Researcher, Department of Urology, University of British Columbia (UBC), Canada" "Co-founder & CEO, Hangzhou Niu'anjin Biotech Co., Ltd." "Researcher, School of Pharmacy, Zhejiang University" "Selected into Zhejiang Province High-Level Overseas Talent Introduction Program" "Ph.D. in Bioinformatics, Zhejiang University & Washington University, USA" At the same time, Dr. Mo focuses on using computer methods such as AI to explore tumor development mechanisms and develop personalized precision therapeutic drugs based on neoantigens. After returning to China, he led his team to achieve clinical translation of personalized tumor vaccines, obtaining IND approval from both the Chinese NMPA and US FDA. This is the first customized drug in China and the first globally customized drug with dual reporting. His research has been published in 40+ international top journals including European Urology (IF: 24.3), Genome Biology (IF: 17.9), Clinical Cancer Research (IF: 13.8), JAMA Oncology (IF: 33), and Cancer Research (IF: 13.3). He has received the Second Prize of Zhejiang Provincial Science and Technology Progress Award, 16 national invention patents, 2 utility model patents, and 28 software copyrights. Mr. Fei Caiyi graduated with a Ph.D. in Biological Information Science from Zhejiang University of Science and Technology, under Professor Liu Haiyan. He has many years of research experience in molecular dynamics simulation and high-throughput sequencing, and has successfully developed multiple clinical high-throughput sequencing analysis platforms. He has published multiple papers in journals such as science advance and npj vaccines and obtained multiple invention patent authorizations. As co-founder of Chengshi Biotech, he is responsible for identifying, optimizing, and conducting clinical research on mRNA drug targets. He led his team to develop platforms for systematic identification of cross-species immune epitopes,体液 immune antigen design, and mRNA sequence optimization.

On June 9, 2026, during the 11th Advanced Therapy Innovation Summit (ATMP 2026), Frost & Sullivan (hereinafter referred to as “Frost & Sullivan”) in collaboration with Cytiva and other industry partners published the ‘In vivo CAR-T Industry Blue Book’ in Guangzhou. Mr. Mao Hua, Senior Partner and Managing Director of Frost & Sullivan, Ms. Song Rongli, General Manager and Scientific Founder of Chengdu Wishen Biopharmaceutical Technology Co., Ltd., Mr. Zhang Yongke, Chief Scientist and Senior Vice President of Nanjing Reindeer Biology, Mr. Wang Yamin, COO of Shenzhen Hongxin Biotech Co., Ltd., Mr. Zhang Shuren, COO of Shenzhen Puijiu Biopharmaceutical Co., Ltd., Mr. Xue Bofu, CSO of Shenzhen Shenyan Biotech Co., Ltd., Mr. Meng Weian, CTO of Yunzhou Biotech (Guangzhou) Co., Ltd., Ms. Luo Fang, General Manager of Cytiva Gene Drug Operations, and Ms. Sun Yingying, Senior Director of Cytiva China and Strategy, attended and witnessed the release of the ‘Blue Book’. At the release ceremony, Mr. Mao Hua, Senior Partner and Managing Director of Frost & Sullivan provided a brief interpretation of the main contents of the ‘In vivo CAR-T Industry Blue Book’. 🌟 Key contents of the Blue Book are presented below 🌟 ✓ Review of the development path of cell immunotherapy ✓ Positioning of in vivo CAR-T technology ✓ Comparison of technical approaches (viral vs. non-viral) ✓ Clinical and industrial trends of in vivo CAR-T ✓ Industry significance and future prospects Ms. Luo Fang, General Manager of Cytiva Gene Drug Operations, explained the purpose of compiling the Blue Book by Cytiva as the initiator, and Dr. Zhang Yongke, Chief Science Officer and Senior Vice President of Reindeer Biology, shared his outlook on the development prospects of in vivo CAR-T technology. Ms. Luo Fang, General Manager of Cytiva Gene Drug Operations: The most valuable aspect of the In vivo CAR-T Industry Blue Book is not the content itself, but its “collective nature”. It brings together real experiences and long-term thoughts from the industry, academia, and clinical fields, representing the common understanding of scientists, doctors, enterprises, and ecosystem partners. In such a rapidly changing frontier field: No single institution can define the future alone, but through consensus, we can get closer to the future. Dr. Zhang Yongke, Chief Science Officer and Senior Vice President of Reindeer Biology, said: as a representative cutting-edge technology of next-generation CAR-T, in vivo CAR-T is making a crucial transition from proof of concept to clinical validation; its indications have expanded from blood cancer and autoimmune diseases to solid tumors. The dual evolution of technology and clinical research means that in vivo CAR-T is gradually ready for large-scale and accessible applications. Frost & Sullivan and Cytiva hope that the release of this ‘Blue Book’ will provide a more systematic research reference and communication foundation for all parties in the industry. Together with the industry, academia, investment institutions, and clinical fields, we will focus on the long-term development of in vivo CAR-T technology and drive the global cell therapy industry to a new stage. Here, we would like to express our gratitude to the following co-signatories for their strong support in industry exchanges, technical discussions, and industrial practice sharing (sorted by the first letter of the company name): ■ Bluepeak Partner LLC ■ Chengdu Wishen Biopharmaceutical Technology Co., Ltd. ■ Chengdu Zhenyu Biopharmaceutical Technology Co., Ltd. ■ Purbing Biotech, a subsidiary of Genentech Co., Ltd. ■ Nanjing Reindeer Biotechnology Co., Ltd. ■ Shanghai Heyuan Biotechnology (Group) Co., Ltd. ■ Shanghai Zhaowei Technology Development Co., Ltd. ■ Shenzhen Hongxin Biotech Co., Ltd. ■ Shenzhen Puijiu Biopharmaceutical Co., Ltd. ■ Shenzhen Shenyan Biotech Co., Ltd. ■ Yunzhou Biotech (Guangzhou) Co., Ltd. At the same time, we would like to express our sincere thanks to the experts who provided professional guidance and cutting-edge insights during the preparation of the Blue Book (sorted by the first letter of the name): ■ Professor Chen Zhu Director and Chief Physician of the Rheumatology and Immunology Department at the First Affiliated Hospital of the Chinese Academy of Sciences (Anhui Provincial Hospital) ■ Dr. Xianghong Li Bluepeak Managing Director & Partner ■ Professor Shen Lin Director of the Digestive Oncology Department at Peking University Cancer Hospital, Director of Phase I Clinical Ward, and Director of the Beijing Key Laboratory of Solid Tumor Cells and Gene Therapy ■ Professor Wang Shuhang Chief Physician at the Cancer Hospital of the Chinese Academy of Medical Sciences, Professor at the National Cancer Center of the Chinese Academy of Medical Sciences ■ Professor Yang Hanbo Founder of Zhenyu Biotech and leader of the cell engineering technology direction of the “Minshan Action” program ■ Professor Zhang Yi Biocell Therapy Center at the First Affiliated Hospital of Zhengzhou University

Background of the Collection With the accelerated implementation of large models, generative AI, and Agents , corporate marketing is moving from the “digital tool application stage” to the “AI-driven systematic transformation stage”. Under the background of deep integration of AI in content production, media placement, customer operations, channel collaboration, and decision optimization, the organization methods, cost structure, and value creation logic of marketing activities are undergoing fundamental changes. More and more companies are deploying AI capabilities in real business scenarios, promoting marketing from localized efficiency improvement to full-link intelligence. In this context, how marketing truly creates sustainable value in an AI environment and constructing industry-relevant best practice examples has become a common concern for enterprises, industries, and research institutions. Considering the above background, Frost & Sullivan (hereinafter referred to as “Frost & Sullivan”) and LeadLeo Research Institute will launch a vendor case collection titled “2026 Best Practices in Marketing under Chinese AI Environment”, aiming to systematically identify practical cases where AI has empowered marketing and achieved substantial results in real business scenarios, accumulate reusable methodologies and implementation models, and promote the large-scale application and value realization of AI across the entire marketing chain, providing a reference framework for the long-term improvement of Chinese enterprises’ marketing capabilities. Meanwhile, the research findings of “2026 Best Practices in Marketing under Chinese AI Environment” will be officially released at the 20th Frost & Sullivan Global Growth, Innovation and Leadership Summit and the 5th New Investment Conference. The Frost & Sullivan Summit will bring together experts from well-known domestic and international enterprises, investment institutions, academia, and media for exchanges. In 2026, it is expected to attract over 300 prominent guests from home and abroad, featuring more than 120 insightful speeches/roundtables, with an estimated audience of over 5,000 professionals, possessing broad industry influence and high dissemination potential. Purpose of the Collection “2026 Best Practices in Marketing under Chinese AI Environment” focuses on the actual application scenarios where AI technology is deeply integrated into the entire marketing chain. It systematically studies the implementation paths and performance outcomes of AI in key areas such as content production, user engagement, conversion improvement, customer operations, and marketing decision-making, covering Retail and Fast-Moving Consumer Goods, Cross-Border E-commerce, Real Estate and Home Improvement, Pan-Internet, Education & Training, Automotive & Mobility, Culture & Tourism, Industrial Manufacturing, Finance and Healthcare & Life Sciences key industries. This report will conduct systematic, comparable, and industry-reusable research on enterprise cases through a unified evaluation framework and multi-dimensional assessment system, ultimately forming industry-relevant best practice cases in AI marketing, providing references for enterprises to improve marketing efficiency, optimize cost structure, and enhance growth quality in an AI environment. Frost & Sullivan, in collaboration with LeadLeo Research Institute, has officially launched the vendor case collection activity. We sincerely invite vendors to participate in this report collection, jointly promoting the deep application and practical innovation of AI in corporate marketing scenarios, constructing industry-relevant best practice examples, and facilitating the systematic upgrade of Chinese enterprises’ marketing capability systems. Key Research Points 1. In-depth Interpretation of the List 1. What are the application boundaries and value reconstruction paths of AI in the entire marketing chain? How can the optimal integration points of AI in insight, content, placement, conversion, operation, and decision-making be determined? 2. Which marketing scenarios are most suitable for first adopting AI? How is their maturity evaluated? How can the real business value of marketing practices in an AI environment be measured? 3. How can marketing practice cases in an AI environment achieve stable operation and sustainable evolution? What are the replicability and scale-up paths of excellent cases? 2. Selection of High-Quality Entities The entities focused on in this report’s research and selection focus on marketing practice cases that have achieved real results in an AI environment, driven by AI technologies such as large models and Agents, as well as enterprise customers who have deployed AI marketing solutions in real business scenarios and achieved quantifiable business results. Ultimately, benchmark practice cases in AI marketing development levels across various industries are selected. Value of Participation Vendors participating in this report collection will have the following opportunities: 1. By being selected as best practices, they can gain trust from markets and users, enhancing brand industry influence; 2. Being selected as best practices can boost corporate competitiveness and attract potential customers and partners; 3. The exposure of best practice reports helps investors understand the company’s potential and market prospects, attracting investors and partners; 4. By using selected best practice cases, they can establish connections with leading enterprises in other industries and explore cross-industry cooperation opportunities; 5. They have the opportunity to be invited to attend online/offline report insights sessions organized by LeadLeo, engaging in exchanges with industry experts and investment institutions. List Establishment This report establishes a three-dimensional evaluation system consisting of technical performance and innovation, implementation and service support, and customer experience and satisfaction feedback, to systematically and comparably assess vendor AI marketing application cases across different industry scenarios. Based on the comprehensive scoring results, the report selects the top two cases in each industry as best practice solutions, and also displays the corresponding vendors and enterprise customers, reflecting the overall competitiveness and implementation maturity of AI marketing solutions in different industrial scenarios. Selection Rules This best practice selection will be conducted by Frost & Sullivan, in collaboration with LeadLeo Research Institute, forming a panel of nearly 100 expert judges. The judges will conduct group evaluations based on the areas each expert is proficient in. 1. Adopting a selection method combining active screening by the organizer and voluntary submission of materials by enterprises, to maximize coverage, increase participation, and enhance the rationality and reference value of the final selection results. 2. After enterprise materials are entered into the selection system, the expert team responsible for the respective industry will conduct comprehensive evaluations of the indicators of the selected entities according to the selection criteria, and select the top two with the highest comprehensive scores as best practice solutions. Research Release Plan Project launch date: June 1, 2026 First round of registration deadline for the list: June 22, 2026 Second round of material submission deadline: July 3, 2026 Notification of list selection results: July 10, 2026 Official release of the report: August 5, 2026 Release Channels The 20th Frost & Sullivan Global Growth, Innovation and Leadership Summit and the 5th New Investment Conference; 14 mainstream reporting platforms including LeadLeo Technology & Innovation Network, Wind, and Choice, supplemented by LeadLeo’s self-media matrix (LeadLeo Technology & Innovation Network, WeChat, Weibo, Toutiao, Xueqiu, Futu, SHCN, etc.) for promotion. It will reach over 5,000 high-quality media and investment institutions, helping selected enterprises gain high market attention and enhanced brand value. Participation Process From now until June 22, 2026, enterprises can scan the QR code to fill out the registration form and enter the first round of registration; Initial screening stage: The judge team will conduct preliminary screening based on enterprise information and application directions; Second round submission: Shortlisted enterprises will receive an email notification and need to submit the registration form by July 3; Result announcement: The selection status is expected to be notified via email around July 10; Results release: The research findings will be published along with the list and report on August 5, 2026. Long-press to recognize the QR code and participate in the selection

Recently, Frost & Sullivan released a brand story film titled "Trust, Seeing the Future" on the occasion of its 65th anniversary. The film highlights the core values that Frost & Sullivan has adhered to over 65 years: facts precede opinions, and trust begins with professionalism. 价值观共鸣：信任，是穿越周期的共识 Frost & Sullivan’s development began in the early 1960s. At that time, the global economy was steadily recovering, expanding in scale, and technological revolution drove significant productivity upgrades. International trade and investment were growing rapidly, business boundaries were expanding, and there was an unprecedented demand for specialized and objective consulting services in the market. In 1961, Lor Frost & Sullivan Daniel Frost & Sullivan With their deep understanding of business fundamentals and keen analysis of industry trends, the two individuals jointly established Frost & Sullivan in New York, USA. In a regular lunchtime discussion, the two founders established Frost & Sullivan’s principle that "facts precede opinions," marking the beginning of the brand’s 65-year journey. In this journey, Frost & Sullivan’s vision has expanded from the United States to the global stage. In the 1970s, it established offices in European financial centers such as London and Frankfurt. Subsequently, in the 1990s, it entered Asia and set up operations in China, Japan, Singapore, and India, gradually building a global service network. After 65 years of development, Frost & Sullivan’s business now covers nearly 50 countries and regions worldwide, serving clients across the globe, including Fortune 500 companies such as Procter & Gamble, Unilever, Coca-Cola, BMW, Siemens, Amazon, and Johnson & Johnson. It can be said that trust is the foundation that has enabled Frost & Sullivan to grow from a technology insight firm into a globally recognized growth consulting and investment services company. "The starting point of trust stems from a shared set of values," said Zuyaju, President and Managing Partner of Frost & Sullivan globally. Having been deeply involved in the industry for over thirty years, he firmly believes that the deepest and most lasting connection between brands and customers always lies in shared ideals and value alignment. Deeply focusing on the local market: Trust is the journey of mutual achievement. In March, Frost & Sullivan’s Asia-Pacific headquarters was established in Shanghai, indicating a further intensification of its strategy in the Asia-Pacific region, especially within China. Since entering China in 1998, Frost & Sullivan has adhered to a localization strategy, with Chinese partners leading operations and driving localization efforts; to date, Frost & Sullivan has nearly 500 consultants and analysts in China, covering 19 core industries of the national economy and over 6,000 niche markets. A strong foundation of professional research forms the basis of trust in each collaboration. Frost & Sullivan serves both the localization growth of international giants and the global expansion of Chinese enterprises. Nameuan优品, Laopu Gold, Pop Mart, SenseTime, Midea Group, SF Holdings, Hengrui Medicine, Sany Heavy Industry, Shenghong Technology — at critical moments of their listing, Frost & Sullivan acts as an independent industry advisor to establish a professional and reliable communication bridge. Dr. Wang Xin, Senior Vice President Global, Co-Chair of Asia Pacific Region, and Chairman of Frost & Sullivan China, summarized it as: "The deepest trust is built upon the journey of mutual achievement." Taking Pop Mart as an example, during its critical transformation period in 2016, Frost & Sullivan first defined the concept of the "trendy toys" industry, and predicted that the global market size would reach $41.8 billion in 2024. Subsequent market developments confirmed this prediction, and Pop Mart has grown into a global trend brand integrating design, production, and sales. This professional foresight has been validated through trust in business practice. In the past 36 months (as of March 31, 2026), Frost & Sullivan has served 195 Hong Kong stock IPO projects, holding a market share of 71%. Since 2003, it has helped nearly three thousand companies go public. The trust from the capital market has indeed become Frost & Sullivan’s competitive advantage. Trusted Knowledge Network: Trust, Traceability, Verifiability Trust comes from growth, and more from methods. Wang Chenhui, Partner and President of Frost & Sullivan China, defines this traceable, verifiable, and transferable methodology as "Trusted Knowledge Network (KNIT)"—a continuously evolving, proactive, and transparent knowledge system. “Trust comes from verifiable science,” Wang Chenhui said. Over the past 65 years, Frost & Sullivan has continuously updated its research tools, from early tape data storage to the AI+HI intelligent analysis platform. Both its three predictions on industrial automation in 2012 and its assessment of autonomous driving by 2030 were widely recognized in the industry. Entering the AI era, AI search is developing at an unprecedented pace. According to the 57th... Statistical Report on the Development Status of China's Internet 'Frost & Sullivan' 'Frost & Sullivan China' 'LeadLeo' 'LeadLeo Research Institute' 'LeadLeo' 'YUAN CAPITAL' 'SULLIVAN TELE-TREND CLOUD TECHNOLOGY' 'TradeGo' 'MagnaTEC' 'Automotive & Mobility' 'Environmental Protection & Energy Saving Technology' 'Logistics & Supply Chain' 'MATERNAL AND INFANT' 'Education & Training' 'Real Estate & Property' 'Catering & New Retailing' 'Advanced Materials' 'Healthcare & Life Sciences' 'Semiconductor & Chip' 'COMMERCIAL AVIATION' 'Technology, Media and Telecom' 'LANDSCAPING' 'Big Data & AI' 'Infrastructure Construction & Utilities' 'Culture & Entertainment' 'AGRICULTURE, FORESTRY ANIMAL HUSBANDRY AND FISHERY' 'Food & Beverage' 'Fintech' 'SHIPPING AND PORTS' 'Dual Carbon & New Energy' 'Mining & Metals' 'Public Sector' 'Cross-Border E-commerce Trade' 'Building Technology, Construction & Decoration' 'Beauty & Fashion' 'Smart Homes' 'Digital Infrastructure' 'Enterprise Services' 'Consumer Electronics' Frost & Sullivan, in collaboration with others, addresses AI's transformation of the information ecosystem LeadLeo Research Institute Frost & Sullivan releases '2025 AI New Era Brand Value Management White Paper' to alert against language pollution risks. Wang Chenhui stated that the KNIT system helps companies gain sustainable dominance in perception during this transformation. "By leading 'technology for good' through professional practices, we can establish industry-wide 'trust' guidelines," he said. Technology for Good: Trust is a social responsibility Wang Chenhui stated at the 2026 Global South Asset Management Forum that as AI becomes more widely used in investment analysis, industry research should shift from "closed-source" to "open-source" approaches. Frost & Sullivan will, under regulatory guidance, use transparent research methods to clearly present investors with data sources, analysis models, and research logic, ensuring that the research process is traceable and verifiable. In January this year, under the leadership of the Frost & Sullivan China, nearly 30 institutions jointly released the "Joint Initiative on Trustworthy Content Sources in China’s Digital Marketing Industry" at the Frost & Sullivan China, calling for the establishment of a trustworthy ecosystem. Wang Xin said, "We have a responsibility to spread ‘trustworthy’ research methods." Since 2023, Frost & Sullivan has continuously organized the National College Students Industry Research Competition, attracting thousands of students each year and enabling “trust” to be passed down through industry talent development. "We are a company focused on the future." Wang Xin said that Frost & Sullivan has 65 years of experience proving that in complex and changing business environments, relying on professionalism and trust can help overcome challenges and achieve sustainable growth.

The twenty-first Frost & Sullivan Global Growth, Innovation and Leadership Summit and the fifth New Investment Conference (hereinafter referred to as '2026 Frost & Sullivan Summit' or 'Conference'), organized by Frost & Sullivan, a leading global growth consulting firm, will be held grandly in Shanghai from August 4-5, 2026. During the conference, a High-Level Forum on New Investments in Life Sciences will be launched. The forum includes three parallel sessions focusing on biomedicine, medical devices, and health technology, presenting cutting-edge topics and latest insights. With the core concept “Innovation Drives Change, Resilience Leads to Success”, the forum invites industry leaders, biomedicine and medical device companies, health technology firms, investment institutions, and professional services organizations to deeply discuss emerging trends in life sciences, innovative technologies, and global development paths, aiming to promote industrial advancement and global collaboration. Host City: Shanghai, China Date: August 4-5, 2026 Conference Scale: 5,000+ Conference Format: Offline + Online Live Streaming Organizer: Frost & Sullivan 01 Agenda Framework of the Conference August 5 9:00-17:00 High-Level Forum on New Investments in Life Sciences (Parallel Session) – Biomedicine Track 9:00-17:50 High-Level Forum on New Investments in Life Sciences (Parallel Session) – Medical Devices Track 9:00-17:40 High-Level Forum on New Investments in Life Sciences (Parallel Session) – Health Technology Track 02 Highlights of the Conference ●High-Level Forum on New Investments in Life Sciences (Parallel Session) – Biomedicine Track Hot Terrain, Innovative Voyage All day on August 5 As the industry cycle shifts from capital frenzy to rational development, China’s biopharmaceutical industry uses innovation as its weapon and globalization as its shield, establishing a new direction in value reconstruction. Immunotherapy has gone beyond the single success of CAR-T to make deep breakthroughs in multiple technologies such as TCR-T and CAR-NK. Advances in solid tumor treatment and general products indicate that cell therapy enters a new era of “multi-arms collaboration”. ADC 、RDC and gene drugs are advancing in multiple fields. Global expansion has evolved from a vision into a strategic restructuring. This is not just a simple technological iteration, but a crucial leap for Chinese innovative drugs from “following” to “leading”. On this promising ground, Zhizhou has set sail. ●Life Science New Investment Summit Forum (Parallel Event) – Medical Devices Session Innovation knows no bounds, medical devices achieve great things All day on August 5 When intelligent technology integrates with other fields, breaking traditional boundaries, medical devices are transitioning from single manufacturing to an ecosystem. AI image recognition and intraoperative decision-making are no longer just auxiliary tools, but new engines for reshaping the healthcare value chain. The overseas strategy has undergone a qualitative change from product export to value chain restructuring. Under the new normal of centralized procurement, commercialization logic is redefining growth trends through “breakthroughs” rather than “adaptation”. Medical devices achieve great things because they become key variables in reconstructing medical costs and accessibility. ●Life Science New Investment Summit Forum (Parallel Event) – Health Technology Session Zhizhi Life, reshaping health All day on August 5 Health technology is experiencing a fundamental paradigm shift: from fragmented technical breakthroughs to systematic intervention throughout the life cycle. The core feature of the current landscape is the deep integration of data, algorithms, and biotechnology—AI is no longer an auxiliary tool, but a new engine driving target discovery and efficacy prediction. As engineered cell technology breaks through the traditional medical limitation of “only repairable, difficult to rebuild”, health technology will move from “curing diseases” to “shaping life”, extending from functional recovery to the unity of aesthetics and quality of life. A more systematic and predictive future for health is being written together by today’s technology integrators and ecosystem builders. 03 Agenda Life Science New Investment Summit Forum (Parallel Event) – Biopharmaceutical Session Start End Content 9:00 9:30 Check-in 9:30 9:35 Opening Speech 9:35 10:00 Keynote Speech 1 "The Window, Rules, and New Capital Direction of HKEX IPOs in the New Cycle" 10:00 10:25 Keynote Speech 2 "Portrayal and Evaluation of High-Quality Chinese Biopharmaceutical Assets in the Eyes of MNCs" 10:25 10:50 Keynote Speech 3 "Global Benchmarking and Biopharmaceutical Ecosystem Development of Large Chinese Pharmaceutical Companies" 10:50 11:05 Coffee Break 11:05 11:15 ‘2026 China Biopharmaceutical Internationalization Development Blue Book’ Released 11:15 12:15 Panel Discussion 1 Next Step of Going Global: From “Ready to Go Global” to “able to Take Root” 12:15 13:25 Lunch Break 13:25 13:50 Keynote Speech 4 Financing Logic and Value Restructuring in the Primary Market under the “New Normal” 13:50 14:00 ‘2026 Global Gene Therapy Industry Development Blue Book’ Released 14:00 14:25 Keynote Speech 5 Technical Breakthroughs and Industrial Prospects of In-Vivo CAR-T 14:25 14:50 Keynote Speech 6 Key Technological Breakthroughs and Precise Construction of the 3D Cell "Intelligent Manufacturing" Platform 14:50 15:05 Tea Break 15:05 15:30 Keynote Speech 7 The Innovative Wave in Peptide Drug Development and the Paradigm Shift in New Drug Discovery 15:30 15:55 Keynote Speech 8 Strategies and Practical Paths for Drug Development in Innovative Disease Areas 15:55 16:55 Panel Discussion 2 AI Reconstructs the Innovation Paradigm: How Chinese Biopharmaceuticals Can Utilize AI for "Intelligent Transformation" 16:55 17:00 Host’s Closing Statement Life Science New Investment Summit Forum (Parallel Event) – Medical Devices Session Start End Content 9:00 9:30 Check-in 9:30 9:35 Opening Speech 9:35 10:00 Keynote Speech 1 Technological Evolution of High-End Medical Devices: From Fundamental Hardware Innovation to Multimodal Digital Integration 10:00 10:25 Keynote Speech 2 Innovation and Development of Chinese Medical Devices 10:25 10:50 Keynote Speech 3 Discussion on the Engineering Bottlenecks and Clinical Translation Paths of Invasive Brain-Computer Interface (BCI) Neural Decoding 10:50 11:05 Tea Break 11:05 11:15 Release of ‘Global Brain-Computer Interface Industry Development Blue Book’ 11:15 12:15 Panel Discussion 1 High-Quality Development of Chinese Medical Devices Overseas: Multi-center Clinical Design, Overseas Registration Access, and Localization Operation System 12:15 13:25 Lunch 13:25 13:50 Keynote Speech 4 Precision Medicine – Early Screening and Precision Imaging 13:50 14:15 Keynote Speech 5 Reimagining the Future: The Next Decade of Ophthalmic Medical Equipment in China 14:15 14:40 Keynote Speech 6 Frontier Explorations in the Era of AGI for Medical Imaging 14:40 14:50 ‘2026 Global Digital Medicine Imaging Industry Development Blue Book’ Released 14:50 15:05 Coffee Break 15:05 15:30 Keynote Speech 7 Innovations in Energy and Structure of Cardiovascular Interventional Therapy 15:30 15:55 Keynote Speech 8 Cardiovascular Intervention – Breakthroughs and Rebirth in the Post-Competitive Pricing Era 15:55 16:20 Keynote Speech 9 R&D Innovation and Commercial Practice of Orthopedic Robots 16:20 16:45 Keynote Speech 10 Precision Tumor Diagnosis and Treatment Equipment: Engineering Practices of Boron Neutron Capture Therapy (BNCT) and Intraoperative Fluorescence Navigation 16:45 17:45 Panel Discussion 2 Innovation Paradigm of Interdisciplinary Integration between Medicine and Engineering: From Clinical Pain Points to Closed-Loop Management of Medical Device Systems Engineering 17:45 17:50 Moderator’s Closing Statement Life Science New Investment Summit Forum (Parallel Event) – Health Technology Session Start End Content Guests 9:00 9:30 Check-in 9:30 9:35 Host’s Speech 9:35 10:00 Keynote Speech 1 Reconstructing Medical Visual Intelligence: The Path to Breakthrough in AI Medicine 10:00 10:25 Keynote Speech 2 The New Ecosystem of Medical Services: From Terminal Perception, Data Integration to Intelligent Decision-Making 10:25 10:50 Keynote Speech 3 How Medical AI Achieves a Business Closed Loop in Pharmaceutical Digital Marketing 10:50 11:05 Tea Break 11:05 11:30 Keynote Speech 4 Non-invasive Brain-Computer Interface: AI Digital Therapeutics and the Reimagining of Brain Health 11:30 12:30 Panel Discussion 1 Healthful Hard Technology for National Health 12:30 13:30 Lunch 13:30 13:55 Keynote Speech 5 From "Designable" to "Programmable": The Platform-Based Transition of Synthetic Biology 13:55 14:20 Keynote Speech 6 Crossing the Transformation Gap: Industrialization Pathways and Business Scenarios of Synthetic Biology 14:20 14:45 Keynote Speech 7 Reforming Manufacturing Paradigms: Scalable Pathways and Value Restructuring of Biomanufacturing 14:45 14:55 ‘2026 Global Synthetic Biology Industry White Paper’ Released 14:55 15:10 Coffee Break 15:10 15:35 Keynote Speech 8 New Materials for Regenerative Medicine: Next-Generation Growth Trajectories from Fillings to Tissue Repair 15:35 16:00 Keynote Speech 9 Beyond Traditional Fillers: Agarose Gel’s Tissue Support and Clinical Value Restructuring 16:00 16:25 Keynote Speech 10 Medical Beauty Transformation of Natural Polymer Materials: The Regenerative Potential and Industrialization Path of Silk Fibre 16:25 16:35 ‘2026 Global Animal-Based Collagen Products Development White Paper’ Released 16:35 17:35 Talk Show 2 The Commercialization Turning Point of Regenerative Medical Beauty: New Materials, Clinical Evidence, and Industrial Ecosystem Restructuring 17:35 17:40 Host’s Closing Statement *The specific agenda is subject to the event site 04 GIL Awards Announced The SULLIVAN Growth, Innovation and Leadership Best Practices Award (abbreviated as GIL Awards) aims to recognize outstanding companies that have made significant contributions and achieved leadership positions in various industries. After nearly 30 years of development worldwide, the authority and fairness of this award have been widely recognized by the investment and financial communities, as well as within the industry. To date, over 5,000 excellent companies have been honored globally. 2026 marks the 65th anniversary of Frost & Sullivan’s establishment. Frost & Sullivan China will continue to track numerous entrepreneurial and investment success cases in high-tech and strategic emerging industries throughout 2026. It will conduct objective analysis and comprehensive evaluation of the innovation capabilities, business models, founding teams, technical abilities, and future prospects of the participating companies, and jointly select several outstanding biotech leading enterprises with a professional judging committee. The winners of the 2026 GIL Awards will be announced during this conference At the 65th Anniversary Celebration of Frost & Sullivan’s Establishment and the 20th Anniversary Celebration of Frost & Sullivan Summit in China Now announced. 05 Blue Book Released At this conference, Frost & Sullivan will release seven blue books, covering Hong Kong 18A , biopharmaceutical internationalization, gene therapy, brain-computer interface, digital medical imaging, synthetic biology and animal-derived collagen other cutting-edge sectors, focusing on the forefront of global technological changes and industrial restructuring, and providing in-depth insights into innovation trends and investment directions in the life sciences field. ‘2026 Hong Kong 18A Biotech Industry Development Blue Book’ English and Chinese Version With the acceleration of global innovative drug research and development, the continuous improvement of Hong Kong Stock Exchange’s capital market systems, and multiple factors in China’s biopharmaceutical industry transformation and upgrading, the Hong Kong 18A rules have gone through pilot exploration and entered a mature development phase of standardization and normalization. The reform of China’s biopharmaceutical capital market is being implemented in depth. As a special listing channel for unprofitable biotech companies, the 18A system breaks down the barriers between innovation research and development and the capital market, helping domestic pharmaceutical companies achieve full-chain breakthroughs from clinical development to industrialization. Under this background, Frost & Sullivan has integrated vast data such as the global biotech secondary market conditions, investment and financing in primary and secondary markets, and IPO issuance transactions to compile this blue book: reviewing the ten-year cycle changes in the global biopharmaceutical capital market and the evolution path of 18A policies vertically, analyzing the 18A industry landscape, popular innovation sectors, and the core fundamentals of listed companies horizontally; from Pre-IPO financing, new share issuance to post-IPO secondary market performance, quantitative analysis of valuation and operating data across the entire chain; combining with Hong Kong’s RWA asset tokenization innovation model to explore diversified new financing models for biopharmaceuticals, and including annual IPO agents, listed companies, institutional investments and other authoritative rankings. It also provides in-depth analysis of growth prospects, corporate pipeline value, and commercialization potential in various sectors, offering quantitative data, industry insights, and decision-making basis for enterprise services, consumer electronics, cross-border e-commerce trade, building technology, construction & decoration, beauty & fashion, smart homes, digital infrastructure, enterprise services, consumer electronics, and public sector. [Collaborative Blue Book] Please scan the QR code below, and we will contact you! ‘2026 China Biopharmaceutical Internationalization Development Blue Book’ English and Chinese Version China biopharmaceutical companies’ “internationalization” is an inevitable choice for the Chinese innovative drug industry to actively participate in global industrial division of labor and seek larger market space and higher value realization paths after completing early capacity accumulation. In the past, Chinese biopharmaceutical companies relied more on local clinical resources, engineer advantages, and rapid iteration capabilities to start innovation. However, as local market competition intensifies, payment constraints increase, and homogeneous pipelines grow, internationalization becomes an important direction for companies to break through growth boundaries, verify innovation value, and enhance capital recognition. Meanwhile, global pharmaceutical companies are re-evaluating Chinese innovation capabilities, considering Chinese companies as important research cooperation partners, asset sources, and industrial chain partners. Based on this, Frost & Sullivan releases the ‘2026 China Biopharmaceutical Internationalization Development Blue Book’ to systematically outline the stage characteristics, driving factors, main paths, and future trends of China’s biopharmaceutical companies’ internationalization, and discuss with industry participants, investors, and stakeholders the long-term value and development blueprint of China’s biopharmaceutical industry in global markets. [Collaborative Blue Book] Please scan the QR code below, and we will contact you! English and Chinese Version of '2026 Global Gene Therapy Industry Development Blue Book'" Driven by continuous technological breakthroughs, improved regulatory frameworks, and increased capital investment, the gene therapy industry is rapidly moving from an early technical exploration stage to commercialization. Notably, China’s 15th Five-Year Plan has included biomanufacturing as one of the core directions of strategic emerging industries, and gene therapy has been identified as a key area requiring “significant progress.” Under the 15th Five-Year macro-strategy, gene therapy is no longer merely a market activity driven by technology exploration and capital, but has become a crucial component in building national biological economic competitiveness. It requires systematic improvements in carrier technology, production process upgrades, clinical translation efficiency, and regulatory system enhancements. However, the industry still faces systemic challenges such as complex production processes, insufficient scale production capacity, high shell rate, high costs, long-term data validation, and an imperfect payment system. In this context, Frost & Sullivan aims to provide a comprehensive analysis of the development stages, technical systems, and industrial chain structures of the gene therapy industry through this blue book, including an in-depth examination of key technological barriers, commercialization paths, and market opportunities, offering forward-looking market insights and strategic decision-making references for all industry participants. [Participation Cooperation Blue Book] Please scan the QR code below, and we will contact you! English and Chinese Version of '2026 Global Brain-Computer Interface Industry Development White Paper'" Currently, innovative achievements in the field of brain-computer interfaces in China are emerging continuously, and the industry is developing rapidly, becoming an important area for the deep integration of technological innovation and industrial innovation. By establishing a full-chain ecosystem of “technical research—application scenarios—industrial clustering” and prioritizing review mechanisms, China is accelerating its transition from key technology breakthroughs to global industry leadership, creating new advantages for Chinese enterprises in international competition. In this context, Frost & Sullivan aims to provide a comprehensive analysis of the development stages, structural characteristics, and evolution paths of the industry, including an in-depth examination of key application areas and market opportunities, offering forward-looking market insights and strategic decision-making references for all industry participants to seize opportunities and address challenges. [Participation Cooperation Blue Book] Please scan the QR code below, and we will contact you! English and Chinese Version of '2026 Global Digital Intelligence Medical Imaging Ecosystem Industry Development Blue Book'" As artificial intelligence reshapes countless industries at an unprecedented pace, the healthcare sector is undergoing a profound transformation from “experience-driven” to “data intelligence.” In this transformation, AI medical imaging is undoubtedly one of the most highly focused and clinically valuable sectors. However, this integration is triggering deeper changes: AI is no longer just the “second pair of eyes” for radiologists, but has become a decisive factor in driving the digital intelligence evolution of the medical imaging ecosystem. Starting from the current construction status and pain points of the medical imaging ecosystem, we will analyze how medical imaging AI can empower the ecosystem in the era of AGI, and then envision the future development of the digital intelligence imaging ecosystem. Through this blue book, we hope to enable the public to better understand the development of the medical imaging ecosystem and how AI medical imaging can truly become a partner and digital replica in doctors’ diagnostic processes. English and Chinese Version of '2026 Global Synthetic Biology Industry Development White Paper'" Synthetic biology is widely defined by academia and industry as the third life sciences revolution following the discovery of the DNA double helix structure and the genomic technology revolution. The 2026 Government Work Report clearly states the need to foster and strengthen emerging and future industries, and promote biomanufacturing as a new economic growth point. Synthetic biology and biomanufacturing are no longer just technical issues, but a triple intersection of national security (independent supply chain control), climate agenda (Dual Carbon/Zero-Carbon Negative Carbon), and economic growth (new quality productive forces). Based on long-term insights into global cutting-edge technology and biomanufacturing industries, Frost & Sullivan has launched the '2026 Global Synthetic Biology Industry Development Blue Book', providing a comprehensive industry perspective through an industrial chain panorama, country/region comparisons, and in-depth analysis of regulatory-technological-commercial dimensions, offering a holistic view of industry trends. [Participation Cooperation Blue Book] Please scan the QR code below, and we will contact you! English and Chinese Version of '2026 Global Animal-derived Collagen Product Development White Paper'" With the continuous development of regenerative medicine, medical aesthetics, and biomaterials industries, animal-derived collagen benefits from its natural and complete three-helix structure, excellent biological activity, and long-term clinical application validation, expanding its applications in tissue repair, high-end medical devices, regenerative medicine, and medical aesthetics. Continuous breakthroughs in key technologies such as extraction and purification, and self-assembly, further enhance the functional value of animal-derived collagen and drive the industry toward higher-end and specialized development. As a global important collagen production and consumption market, China is promoting high-quality industry development driven by technological innovation, industrial upgrading, and expanded application scenarios. In this context, Frost & Sullivan, in collaboration with Fierce Biotech, provides a comprehensive analysis of the current development status, technological evolution, industrial chain ecology, market size, competitive landscape, policy environment, and future development trends of the global and Chinese animal-derived collagen industry, which is important for understanding industry development. 06 Highlights from the Previous Event Previous Forum Review: Strengthening Foundations, Navigating Challenges – The 2025 Frost & Sullivan Life Sciences New Investment Summit Successfully Concluded! 07 More Summit Information Consultation Life Sciences New Investment Summit Event Consultation | Sponsorship Cooperation | Participation Inquiry 📞 Conference Consultation Hotline: 021-3209-6800 ext. 8672 📧 Conference Consultation Email: gil@frostchina.com

Since 1961 in New York, a “quick agreement” lunch, to today’s global service network spanning nearly 50 countries, Frost & Sullivan has always focused on one thing: through in-depth research, clarifying complex markets and providing a solid basis for capital market decisions. 28 years ago, the Beijing office began serving global enterprises entering China, marking a new chapter where Frost & Sullivan and the Chinese market grow together—over 10,000 enterprises went public, transformed, and evolved under our guidance, ranging from local innovators to global leaders. This long image captures the key years and milestones in Frost & Sullivan’s 65-year global journey, serving as a testament to our commitment to professional and trustworthy “long-termism”. Now, let us walk together through these 65 years. Seeing the future through trust Foresight Starts with Trust

In March this year, Frost & Sullivan (hereinafter referred to as "Frost & Sullivan") officially launched the "2026 Global Product Innovation Index Series Study Topic" (hereinafter referred to as "Product Innovation Index Study Topic"). Focusing on the contemporary theme of "product innovation," it systematically analyzed global industrial innovation trends and introduced the first "Comprehensive Evaluation System for Product Innovation Index," which attracted extensive attention in the industry. To further explore representative innovation cases and promote the accumulation of industry innovation experiences and value dissemination, Frost & Sullivan has officially launched the “Product Innovation Index Research Special” case collection campaign. It invites outstanding enterprises, brands, and institutions across various industries to submit product innovation cases that are representative of the industry, feature technological breakthroughs, and possess commercial innovation value, thereby creating a benchmark for industrial innovation. Background: Why is it necessary to redefine "product innovation"? Currently, global business innovation is surging, and AI-driven technological revolutions are transforming various industries. In 2026, as the beginning year of the "15th Five-Year Plan", China’s business environment is undergoing profound transformation. The past extensive growth model based on channel expansion and marketing spending is no longer viable. Shifting consumer demands, rapid technology penetration, and evolving policy guidelines are reshaping the competitive landscape for businesses. Whether it is the health-oriented upgrades in the beverage industry, the efficacy innovations in personal care and beauty products, or technological breakthroughs in smart mobility, AI applications, and consumer electronics, these developments confirm a trend: product innovation has shifted from a "bonus factor" in business development to a "key factor" determining future competitiveness. In this context, how can we identify products and companies that truly possess innovative value? How can we establish a scientific, systematic, and measurable innovation evaluation system? How can we summarize innovation patterns through industry cases and support industrial upgrading? Based on long-term industry research, Frost & Sullivan offers a world’s first product innovation index system covering multiple sectors and enabling quantitative comparison. Through monthly reports, it systematically decodes the underlying logic and implementation methods of product innovation, providing authoritative decision-making support for enterprises. The current case collection aims to select breakthrough product innovation practices from various fields as core samples for the product innovation index research. Selected cases will serve as industry innovation benchmarks and receive comprehensive support and exposure. Evaluation Criteria: How to quantify the value of innovation benchmarks? Frost & Sullivan Frost & Sullivan China LeadLeo Research Institute LeadLeo YUAN CAPITAL SULLIVAN TELE-TREND CLOUD TECHNOLOGY TradeGo MagnaTEC Automotive & Mobility Environmental Protection & Energy Saving Technology Logistics & Supply Chain MATERNAL AND INFANT Education & Training Real Estate & Property Catering & New Retailing Advanced Materials Healthcare & Life Sciences Semiconductor & Chip COMMERCIAL AVIATION Technology, Media and Telecom LANDSCAPING Big Data & AI Infrastructure Construction & Utilities Culture & Entertainment AGRICULTURE, FORESTRY ANIMAL HUSBANDRY AND FISHERY Food & Beverage Fintech SHIPPING AND PORTS Dual Carbon & New Energy Mining & Metals Public Sector Cross-Border E-commerce Trade Building Technology, Construction & Decoration Beauty & Fashion Smart Homes Digital Infrastructure Enterprise Services Consumer Electronics In this context, analyzing the core factors of product innovation and establishing a multi-dimensional quantitative evaluation system that combines scientificity and practicality is essential to overcome the subjectivity of qualitative assessments. Defining the key indicators and quantitative standards for each aspect of innovation becomes a pressing need to transform innovation from "blind attempts" into "precision empowerment," and it also serves as a crucial support for enterprises to gain an advantage in innovation and achieve long-term success. In order to objectively measure the innovation potential of enterprises and products, Frost & Sullivan has developed a comprehensive evaluation system for Product Innovation Index. This system aims to penetrate surface levels through quantification, enabling horizontal comparison and vertical growth assessment between enterprises and brands across different sectors and development stages. The comprehensive evaluation system for Product Innovation Index includes multiple levels of indicators. First-level indicators (8 major pillars): Track potential, technological innovation, business innovation, corporate performance, business potential, user experience, marketing operations, and social responsibility. Second-level indicators (19 key elements): Covering category definition rights, cross-sector vitality, user acquisition efficiency, and business growth quality. Three-level indicators (40 hardcore metrics): Based on the R&D expense ratio, overall product market share, user perception, Carbon Footprint Disclosure Frost & Sullivan Frost & Sullivan China LeadLeo Research Institute LeadLeo YUAN CAPITAL SULLIVAN TELE-TREND CLOUD TECHNOLOGY TradeGo MagnaTEC Automotive & Mobility Environmental Protection & Energy Saving Technology Logistics & Supply Chain MATERNAL AND INFANT Education & Training Real Estate & Property Catering & New Retailing Advanced Materials Healthcare & Life Sciences Semiconductor & Chip COMMERCIAL AVIATION Technology, Media and Telecom LANDSCAPING Big Data & AI Infrastructure Construction & Utilities Culture & Entertainment AGRICULTURE, FORESTRY ANIMAL HUSBANDRY AND FISHERY Food & Beverage Fintech SHIPPING AND PORTS Dual Carbon & New Energy Mining & Metals Public Sector Cross-Border E-commerce Trade Building Technology, Construction & Decoration Beauty & Fashion Smart Homes Digital Infrastructure Enterprise Services Consumer Electronics Direction of Collection: Which cases are worth highlighting? The research topic on Product Innovation Index will be presented through monthly reports to systematically decode the underlying logic of product innovation. This case collection is based on a global innovation perspective, aiming to identify Chinese enterprise innovation benchmarks with outstanding innovation capabilities in core technologies, user value, and business models, including but not limited to: Category definers Focusing on product features and design concepts, it has created new niche markets and holds a very high market share among consumers. Technology Breakthroughs Possessing core technology patents, it drives product innovation through technological advancements, achieving significant technical breakthroughs and industrial applications. Pattern Reconstructor Frost & Sullivan demonstrates unique performance in business models, supply chain collaboration, and digital operations, including digital operations, channel innovation, supply chain collaboration, platform ecosystem development, and cross-sector integration. Value Leader In ESG Frost & Sullivan China demonstrates outstanding performance in areas such as green supply chain, circular economy, and social responsibility, and has identified new paths to high-quality growth. Users who have made significant contributions Frost & Sullivan China demonstrates outstanding performance in digital operations, user engagement, and service experience. By providing accurate insights into consumer needs, it achieves user growth, increased user loyalty, and a redefinition of brand value. Participation Value: Authoritative Endorsement + Industry Empowerment + Multi-dimensional Exposure The selected companies/brands will have the opportunity to: Report Focused Cases Collection Selected for the '2026 Global Product Innovation Index Series Research Report', received professional in-depth analysis, became a core sample for the Product Innovation Index evaluation, and enhanced the industry's innovation recognition. Frost & Sullivan’s authoritative coverage across all channels Frost & Sullivan’s official WeChat account, industry media, and collaboration platforms were simultaneously promoted to expand brand influence. Precise connection to industrial resources Linking capital, channels, and supply chain ecosystem resources to facilitate the commercialization of innovative outcomes; Benchmarking with top industry standards Participating in online/offline report insights sessions, engaging in discussions with industry experts and investment institutions. Global Industry Benchmark Invited to attend the 2026 Frost & Sullivan Summit in person, engage in discussions with global investors, enhance international competitiveness, and accelerate progress on the international stage. 2026 Research Release Plan ● Published Projects (Click on the blue text to view) March: '2026 Global Product Innovation Index Series Report No. 1: The Paradigm Shift and Future Ecosystem in Smart Home Industry' April: '2026 Global Product Innovation Index Series Report No. 2: Transformations in MATERNAL AND INFANT Products Industry and Innovation Practices of Key Categories' May: Frost & Sullivan Frost & Sullivan China’s Third Report in the 2026 Global Product Innovation Index Series: New Paths for Smart Water Purification Home Appliances, Insights on Front-Load Filters ● Future Challenges and Planning Drink Products: Studies product innovation, supply chain innovation, store model innovation, and overseas expansion cases. Pet Products: Focus on pet food, smart products, pet healthcare and service innovation. Smart Wearable Devices: Focus on innovation in products such as AI smart glasses, smart bracelets, and smart wearables. Functional Beverages: Focus on energy drinks, sports nutrition beverages, Chinese health water products, etc., with emphasis on product formulation innovation, consumption scenario innovation, brand innovation, and channel innovation practices. Robots: Focus on exploring the technological innovation pathways and business models of products such as humanoid robots and service robots. Beauty and Skincare: Focus on efficacy-based skincare, beauty devices, and AI-driven beauty innovation areas. Outdoor Lifestyle: Focus on camping equipment, cycling, smart wearables, and scenario innovation. New Types of Beverages: Focus on low-alcohol drinks, pre-mixed drinks, plant-based beverages, and innovative practices of new consumer brands. Age-friendly Products: Focus on age-friendly products, health management, and innovative practices in elderly care services. More industry research projects are being planned continuously. In the future, we will focus on innovation trends in various fields for an extended period, explore product innovations in additional areas, and consistently deliver professional and authoritative research findings. Registration methods Long press to recognize the QR code below

Over the past decade, CAR-T therapy has made significant breakthroughs in blood tumors, demonstrating the great potential of engineered immune cell therapy. However, traditional ex vivo CAR-T still relies on personalized preparation, involving multiple steps such as cell collection, gene modification, amplification, quality control, transportation, and reinfusion. The treatment cycle is relatively long, and the manufacturing costs and supply chain complexity are high. in vivo CAR-T This provides new ideas to overcome the limitations of traditional CAR-T. As a cutting-edge direction integrating cell therapy, RNA drugs, targeted delivery, and genetic engineering, it induces immune cells to express CAR through viral vectors or lipid nanoparticles, enabling “in vivo engineered” treatment, potentially facilitating CAR-T to move from personalized customization to a more standardized and platform-based development model. Under this context, Frost & Sullivan (Frost & Sullivan, hereinafter referred to as “Frost & Sullivan”) in collaboration with Cytiva and other industry partners has released the “In vivo CAR-T Industry Blue Book”. The Blue Book systematically outlines the development background, technical pathways, clinical translation, industrialization challenges, and future trends of in vivo CAR-T, aiming to provide systematic industry insights and research references for the industry, academia, investment institutions, and clinical fields. Twelve leading industry companies have jointly released it, bringing together insights from dozens of top experts— the first Blue Book on in vivo CAR-T cell therapy is released, defining new development benchmarks for the industry. Conference theme: 11th Advanced Therapy Innovation Summit ( ATMP 2026 ) Release date: June 9, 2026 Location: Guangzhou Book the electronic version of the “Blue Book” now

In 2026, AI Agent (intelligent agents) are moving from question-answer assistants and point-based automation tools to task execution systems aimed at real business objectives. Their core value lies not just in conversation tasks, but in their ability to understand tasks, break down processes, call upon tools, and deliver results. Currently, AI Agents have been implemented in general scenarios such as office collaboration, code development, and customer service operations, and are rapidly penetrating vertical industries like e-commerce, finance, and education. Driven by the continuous advancement of “AI +”, improved model capabilities, and a solid digital foundation for enterprises, China’s AI Agent industry entered a stage of deepening applications in H1 2026. The focus of the industry has shifted from concept validation to actual outcomes, and enterprises are more concerned about key metrics such as task completion rate, business ROI, system stability, data security, and permission boundaries. Given these circumstances, Frost & Sullivan Frost & Sullivan (hereinafter referred to as “Frost & Sullivan”) and LeadLeo Research Institute will launch a vendor solicitation for the “2026 China AI Agent Best Practices Application List,” with a research period covering H1 2026. The list will systematically select innovative, leading, and replicable application cases within the industry, summarize common patterns, evaluation criteria, and success paths of AI Agent implementation, establish industry benchmarks, enhance market confidence, and guide resources toward high-value, reliable applications. Source: Frost & Sullivan Analysis Purpose of Solicitation To accelerate the promotion and demonstration of AI Agent innovation, drive technological breakthroughs, industrial upgrading, market maturity, and ecosystem building, the “2026 China AI Agent Best Practices Application List” will comprehensively review and authoritative present the most leading application practices, cutting-edge technology progress, and industry development trends in the AI Agent field, fully showcasing China’s AI Agent innovation capabilities and implementation effectiveness. By selecting best practice applications, the list aims to establish application models, encourage technological innovation, promote collaborative creation among upstream and downstream industries, help expand the global influence of China’s AI Agent technology, and further accelerate the healthy development and ecosystem construction of the AI Agent industry. Frost & Sullivan and LeadLeo Research Institute have officially launched the vendor solicitation activity. We sincerely invite manufacturers to participate in this report, working together to enhance the competitiveness and influence of China’s AI Agent technology worldwide. Key Research Points 1. In-depth Interpretation of the List 1. How is the AI Agent evaluation model constructed? What are the core indicator systems and dimensions? 2. What are the characteristics of the most popular Agent in the year? What trends are observed in user preferences? 3. What key capabilities does a Chinese Agent with global development potential possess? In what aspects does its competitiveness in the international market manifest? 4. Which scenarios do the most practical Agents primarily serve? What implementation capabilities do they demonstrate? 5. What technologies or business models do the most innovative Agents exhibit? How do they lead industry trends? 6. How do the most commercially valuable Agents convert technical value into business value? What market opportunities do they face? 2. Scouting of High-Quality Entities We will conduct a comprehensive scouting of high-quality AI Agent entities, aiming to ensure that the list includes enterprises with the most innovative technology, market potential, and application value through multi-dimensional and comprehensive evaluations, including: 1. General-type Agents 2. Industry-specific Agents 3. Business-oriented Agents 3. Edge-side Agents Value of Participation Manufacturers and enterprises participating in this report solicitation will have the opportunity to: 1. Gain trust from markets and users through the list, enhancing brand industry influence; 2. By participating and being selected into the list, enterprises can strengthen their competitiveness in similar products and attract potential customers; 3. The exposure of the list helps investors understand the enterprise’s potential and market prospects, attracting investors and partners; 4. Using the list platform, establish connections with leading enterprises in other industries and explore cross-industry cooperation opportunities; 5. Have the opportunity to be invited to attend online/offline industry report insights meetings organized by LeadLeo, engage in in-depth discussions with industry experts and investment institutions. Participation Process The selection of this list will be carried out in four steps. First, enterprises submit AI Agent application cases and related materials. Next, the research team will conduct preliminary screening, review, and research on the submitted materials. Then, an expert review panel will evaluate based on application value, innovation capability, implementation effectiveness, and replication potential. Finally, the organizers will announce the selected list and showcase excellent cases through a list release event. Source: Frost & Sullivan Analysis List Structure This list system includes five major evaluation directions, covering core dimensions such as market attention, international potential, application effectiveness, technological innovation, and commercial value, specifically including: the most popular Agent in 2026, the Chinese Agent with the greatest global development potential in 2026, the most practical Agent in 2026, the most innovative Agent in 2026, and the Agent with the greatest commercial value potential in 2026. Source: Frost & Sullivan Analysis Evaluation Rules This list will establish a panel of nearly 100 expert judges composed of Frost & Sullivan, LeadLeo Research Institute, professional investment institutions, university experts, professors, and top research institutions, all at or above industry level. The judges will conduct group evaluations based on the fields each expert specializes in. 1. Adopt a combination of active screening by the organizer and voluntary submission of materials by enterprises, aiming to expand the coverage of the evaluation and improve the participation rate and rationality of the final evaluation results. 2. After enterprise materials are entered into the evaluation system, the corresponding expert team of the list will evaluate various indicators of the AI Agents participating in the evaluation according to the list settings, and select the top 10 enterprises in each listed category. Research and Release Plan Report release channels: LeadLeo Research Institute, Wind, Choice, and 14 other mainstream report release platforms, supplemented by LeadLeo’s media matrix (LeadLeo Research Institute, WeChat, Weibo, Toutiao, Xueqiu, Futu, SHCN, etc.) for promotion. It will reach over 5,000 high-quality media and investment institutions, effectively and quickly spreading value and attracting market attention. Project launch: May 2026 First round deadline for enterprise list submissions: June 22, 2026 Second round deadline for enterprise list submissions: July 3, 2026 Report release (estimated): August 2025 This solicitation starts now and ends on June 22. We cordially invite relevant industry enterprises to participate. Long press to recognize the QR code to join the recruitment

As the Large Model and AI search become widely used, the way users obtain information is undergoing fundamental changes. In the past, brands mainly competed for rankings and clicks on search results pages; now, brands need to enter the realm of AI-generated answers and become credible sources of information that are cited, recommended, and trusted. Under this change, GEO (Generative Engine Optimization) is becoming a new track for brand growth. GEO is a information processing mechanism based on generative artificial intelligence by professional service institutions. While adhering to laws and regulations, platform rules, and ethical requirements, it combines content governance, technical adaptation, credible source development, and multi-channel collaborative dissemination to structure, verify, and optimize relevant information, thereby enhancing its recognizability, understandability, callable nature, verifiability, and recommendation adaptability within generative AI engines. Currently, while the GEO field is developing rapidly, it faces significant challenges such as increasing information pollution risks, uneven service capabilities, inconsistent performance evaluation systems, and competition that restricts the space for compliant entities. There is an urgent need for industry standards and self-regulation. To implement the national overall plan for digital economy and artificial intelligence development, the China Advertising Association officially launched the standardization work in the GEO field in March 2026. It has established industry self-regulation standards and operational guidelines regarding technical capabilities, technical operation norms, service process criteria, compliance management requirements, and performance evaluation systems. The goal is to prevent industry chaos at the source and promote a healthy development pattern where good products dominate bad ones. Given these circumstances, Frost & Sullivan, a global growth consulting firm, officially started the preparation of the "2026 China GEO Industry Development White Paper" under the guidance of the China Advertising Association. This white paper follows the standardization system of the GEO field established by the China Advertising Association and aims to create a systematic understanding framework for the Chinese GEO industry. It provides authoritative references for enterprises to understand the value logic of GEO, grasp application directions, assess the competitive landscape, and learn from industry practices. We sincerely invite GEO service providers, AI search and content intelligent platforms, brand owners, technology service providers, and ecosystem partners to actively participate, collectively review industry practices, analyze trends, reach industry consensus, and jointly build a compliant, transparent, credible, and sustainable GEO industry development ecosystem to support the construction of Digital China. Content of the Report This white paper will be based on industrial research perspectives and multi-source case studies, and will align with the overall deployment of the standardization system in the GEO field by the China Advertising Association. It will construct a systematic understanding framework for the Chinese GEO industry. Focusing on the development logic, application practices, and standardization directions of GEO services, this white paper provides references for enterprises to understand GEO values, seize market opportunities, participate in industry standardization efforts, and make strategic decisions. Core Research Content: Industry Definition and Development Background Clarify the research boundaries and core characteristics of GEO, analyze the formation logic of brand visibility needs after the rise of AI search, and assess the development potential and standardization paths of the industry. 2. Industrial Chain Structure and Commercialization Paths Break down the main service components of GEO, analyze the value division, product forms, pricing models, and differences among service providers, and outline the industry compliance boundaries and behavioral guidelines. 3. Demand Changes and Application Scenarios Analyze the changes in user search habits and the impact of AI answers on consumer decision-making, determine the foundation of GEO demand, and outline typical application scenarios and the path to building a performance evaluation system. 4. Future Trends and Competitive Analysis Assess the development direction, competitive barriers, and key capabilities of the GEO industry, analyze the role of standardization in reshaping the industry landscape, and provide references for enterprises' medium- to long-term planning and compliant development. 5. Benchmark Enterprises and Product Cases Select representative enterprises and product cases, analyze their service models, product capabilities, customer scenarios, and implementation results, and include them as "Credible Generative Engine Optimization (GEO) Typical" cases. This systematically demonstrates the differentiated advantages, compliance practices, and market representativeness of enterprises in the GEO industry, enhancing their industry status and benchmark value. Participation Value The "2026 China GEO Industry Development White Paper" was compiled and released by Frost & Sullivan, under the guidance of the China Advertising Association. LeadLeo provided communication support. The white paper will be widely published on Frost & Sullivan China’s official website, the China Advertising Association’s official website, LeadLeo Research Institute , Windy, Tencent, Shenhua, Oriental Fortune and other financial terminals and professional channels. Participating enterprises will receive a certificate for being included in the "Credible Generative Engine Optimization (GEO) Typical" cases of the white paper. This will systematically showcase their technical capabilities, service capabilities, customer cases, methodology accumulation, and ecological value in the GEO industry, helping outstanding enterprises enhance their industry recognition, professional endorsement, and capital attention in the new AI search space, and jointly promoting a healthy development pattern of "good products dominating bad ones" in the industry. 1. Enhance Industry Status and Brand Influence: Participate in white paper research and case co-creation, obtain authoritative third-party research endorsement under association guidance, and significantly improve the professional recognition, compliance image, and market trust of enterprises in the GEO sector. 2. Gain Industry Insights: Conduct joint discussions on brand needs, technical paths, platform rules, and commercialization trends, providing references for enterprise product iteration, market strategies, and investment communication. 3. Authoritative Case Exposure and Capital Access: Excellent cases will be included in the white paper’s benchmark cases, industry ecosystem map, and series of communication materials. Through the China Advertising Association’s official website, Frost & Sullivan China’s official website, LeadLeo Research Institute, Windy, Tencent, Shenhua, Oriental Fortune and other financial terminals, and over a hundred cooperative media, professional, multi-dimensional, and highly credible brand exposure will be achieved, precisely reaching the capital market and investment institutions. 4. High-End Industry Ecosystem Connection: Prioritize participation in research interviews and closed-door discussions, and engage in top-level industry events such as the 2026 China International Advertising Festival to deeply connect with brand owners, technology providers, content service providers, investment institutions, and industry experts, expand business cooperation, resource docking, and strategic partnerships, and jointly build a compliant, transparent, credible, and sustainable GEO industry development ecosystem. Participation Process 1. Application Registration: Enterprises interested in participation should scan the code to fill out the application form, submit basic enterprise information, and obtain a preliminary framework of the white paper. 2. Participation in Research and Exchange: In subsequent research and exchange activities, submit relevant excellent cases, participate in discussions, and contribute to the writing of the white paper. White Paper Release Plan Targeted Solicitation: Open to GEO service providers, AI search and content intelligent platforms, brand owners, technology service providers, and ecosystem partners. Enterprises related to the GEO industry are welcome to participate. Solicitation Period: June 1, 2026 – July 31, 2026 White Paper Release Date: Expected in October 2026, officially released during the China International Advertising Festival Collaboration Please contact us Long-press to recognize the QR code to participate in recruitment